Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform
(CYBRID-01 Trial)

Recruiting in Palo Alto (17 mi)

+5 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: Elephas

No Placebo Group

Trial Summary

What is the purpose of this trial?

The primary objective of this study is to determine the ex-vivo prognostic accuracy of the Cybrid live tumor diagnostic platform using in-vivo RECIST 1.1 as the reference method.

Eligibility Criteria

Inclusion Criteria

Suspected of or diagnosed with non-small cell lung cancer (NSCLC).

Written informed consent and HIPAA authorization for release of personal health information prior to registration.

Age ≥ 18 years at the time of consent.

See 6 more

Treatment Details

Interventions

Core needle biopsy (N/A)

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Stage IV or metastatic Non Small Cell Lung Cancer (NSCLC)Experimental Treatment1 Intervention

Subjects suspected of or diagnosed with Stage IV NSCLC and meet one of the following criteria: 1. Subjects who are undiagnosed, have undergone imaging and are suspected to have Stage IV lung cancer. 2. Subjects with a Stage I, II, or III diagnosis of NSCLC, who are being re-biopsied after imaging-confirmed progression to metastatic disease 3. Subjects who have a confirmed diagnosis of NSCLC, and have undergone a SOC biopsy procedure and will undergo a separate procedure for the purposes of this study. 4. Subjects who have a previous Stage IV/metastatic NSCLC diagnosis and have already received first line treatment.